8-K: Bio-Path Holdings Secures $87,000 in Financing via Promissory Note with 1800 Diagonal Lending LLC

Bio-Path Holdings enters into a securities purchase agreement for a $100,050 promissory note with 1800 Diagonal Lending LLC, receiving $87,000 after an original issue discount.

Summary

• Bio-Path Holdings, Inc. has entered into a securities purchase agreement with 1800 Diagonal Lending LLC for a promissory note.
• The note has an aggregate principal amount of $100,050 but was purchased for $87,000, reflecting an original issue discount of $13,050.
• The note bears a one-time interest charge of 12% applied on the issuance date, March 28, 2025.
• The note is to be paid in five installments, starting with a $56,028 payment on September 30, 2025, followed by four payments of $14,007 each, due monthly from October 30, 2025, to January 30, 2026.
• Upon an Event of Default, the note becomes immediately due and payable, with the lender entitled to 150% of the outstanding principal, accrued interest, default interest at 22% per annum, and any amounts owed pursuant to the Conversion Right.
• The lender has the right to convert the outstanding principal and interest into common stock upon an Event of Default at a conversion price equal to 65% of the lowest closing bid price for the ten trading days prior to conversion.
• The lender's conversion is limited to ensure they do not own more than 4.99% of the company's outstanding common stock after conversion.
• The issuance of the note and any shares issued upon conversion will not be registered under the Securities Act of 1933.
• The company is obligated to reimburse the buyer's expenses of $7,000 for legal fees and due diligence.
• The company must maintain its corporate existence and comply with 1934 Act reporting requirements while the note is outstanding.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company secures funding, the terms of the agreement, including the high default interest rate and potential dilution, present significant risks.

Positives

• Bio-Path Holdings secures immediate funding of $87,000.
• The agreement allows for flexibility through a conversion option for the lender.
• The company has the right to prepay the note in full at any time with no prepayment penalty.

Negatives

• The company incurs a significant original issue discount of $13,050.
• The default terms are punitive, requiring payment of 150% of the outstanding amount plus a high default interest rate of 22%.
• The conversion option could lead to dilution of existing shareholders' equity.
• The lender can trigger an Event of Default if the company breaches any material covenant or fails to comply with Exchange Act reporting requirements.

Risks

• Failure to make timely payments on the note will trigger an Event of Default.
• Breach of any material covenant could lead to acceleration of the debt.
• The conversion of debt into equity could dilute existing shareholders.
• The company's ability to continue as a going concern is a potential risk factor.
• The company's reliance on exemptions from registration under the Securities Act introduces potential regulatory risks.

Future Outlook

The company intends to use the proceeds from the note for general working capital purposes.

Management Comments

• There are no direct management comments included in the document.

Industry Context

This type of financing is common for small-cap companies, especially in the biotech sector, to fund operations and research when access to traditional capital markets is limited. The terms, including the high default interest rate and conversion option, reflect the higher risk associated with investing in such companies.

Comparison to Industry Standards

• Similar biotech companies often utilize convertible notes or direct placements to raise capital.
• The interest rates and discount rates are within the typical range for such financings, but the default interest rate of 22% is relatively high, indicating a higher perceived risk.
• The conversion feature, allowing the lender to convert debt into equity at a discount, is a standard feature in these types of agreements.
• Comparable companies that have used similar financing structures include XOMA Corporation and Aeterna Zentaris Inc., although the specific terms vary based on the company's financial health and market conditions.

Stakeholder Impact

• Shareholders face potential dilution if the lender converts the debt into equity.
• The company's financial stability is impacted by the debt obligations.
• Employees may be affected if the company faces financial difficulties due to the debt burden.
• The company's ability to invest in research and development could be affected by the need to service the debt.

Next Steps

• Bio-Path Holdings will make five monthly payments to 1800 Diagonal Lending LLC, starting on September 30, 2025.
• The company will need to monitor its compliance with the terms of the note to avoid triggering an Event of Default.
• The company will need to manage its cash flow to ensure it can meet its debt obligations.
• The company will need to maintain its corporate existence and comply with 1934 Act reporting requirements.

Key Dates

Keywords

promissory note, securities purchase agreement, financing, conversion right, event of default, common stock, Bio-Path Holdings, 1800 Diagonal Lending LLC, debt financing